NeuroVive reports positive pre-clinical results in NASH

Lund, Sweden, November 1, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced positive
pre-clinical results with one of its cyclophilin inhibitors, NVP018, in an
experimental model of the chronic and common liver condition NASH (non-alcoholic
steatohepatitis). The NASH project is in line with the company’s updated
business strategy which includes increased and accelerated efforts in moving
high potential discovery projects forward with the aim of out-licensing them in
the preclinical phase.
The present data shows that NVP018 prevents fibrosis development in a well
-validated experimental model of NASH. Further experimental activities with
NVP018 within NASH are ongoing.

In addition, NeuroVive is developing a new class of compounds with a different
mode of action that may offer complementary treatment of NASH. This discovery
project is based on NeuroVive’s core competence in mitochondrial energy
regulation and the partner company Isomerase’s innovative chemistry
capabilities.

“The current experimental result in NASH is an excellent example of the strength
of the research within NeuroVive and the successful collaboration with
Isomerase. The result at hand is an important step forward in our continued
development for out-licensing in this therapeutic area”, said Erik Kinnman, CEO
NeuroVive. “Given the huge patient population and the high unmet medical need,
we see our results and activities in NASH as high potential near term value
drivers and potential revenue sources in NeuroVive’s pipeline.”

The company has implemented a business model going forward that contains two
parts. One part involves high potential large indication projects like NASH, for
out-licensing in the preclinical phase. The second part is to take drugs for
rare diseases with high unmet medical need through clinical development and into
the market. NeuroVive’s core research and development area continues to be
mitochondrial medicine, with the aim to offer new treatment options to patients
with unmet medical needs. There is a continuous growing understanding for the
importance of mitochondrial function in many diseases.

About NASH
NASH – non-alcoholic steatohepatitis – is a progressive disease that can lead to
liver cirrhosis and the development of hepatocellular carcinoma. NASH liver
damage is caused by a buildup of fat and inflammatory changes in the liver. It
is part of a group of conditions called nonalcoholic fatty liver disease (NAFLD)
that is one of the most common conditions worldwide. It is estimated that 20 %
of the global population suffers from NAFLD and about one-third of the
population in the US. There is a strong association between NASH and a variety
of metabolic syndromes like diabetes and obesity. Approximately 3-5 % of
Americans (approx. 15 million people) suffer from NASH and there are currently
no registered drugs for the treatment of this condition.1)

1) Vernon G. et al. Aliment Pharmacol Ther. 2011;34(3):274-85

About NVP018
NVP018 is a potent non-immunosuppressive cyclophilin inhibitor within
NeuroVive’s new compound class Sangamides. In this cyclophilin inhibitor
chemical family, NVP018 is the oral version of its lead compound (NV556) which
has undergone extensive preclinical development.

About NeuroVive
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company
is committed to the discovery and development of medicines that preserve
mitochondrial integrity and function in areas of unmet medical need. The
company’s strategy is to take drugs for rare diseases through clinical
development and into the market. The strategy for projects within larger
indications outside the core focus area is out-licensing in the preclinical
phase. NeuroVive enhances the value of its projects in an organization that
includes strong international partnerships and a network of mitochondrial
research institutions, as well as expertise with capacities within drug
development and production.

NeuroVive has a project in early clinical phase II development for the
prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT
has orphan drug designation in Europe and in the US. The R&D portfolio consists
of several late stage research programs in areas ranging from genetic
mitochondrial disorders to neurological and metabolic diseases such as NASH.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also
traded on the OTCQX Best Market in the US (OTC: NEVPF).

For investor relations and media questions, please contact:
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com
Charles Athle Nelson, NeuroVive US representative, Tel +1 212 961 6277 or
ir.usa@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact
person set out above, at 08:30 a.m. CET on November 1, 2016.